Loading...
Patients on aspirin therapy who present with peptic ulcer bleeding typically discontinue the aspirin to reduce risk for recurrent bleeding. However, does that risk actually outweigh the cardiovascular benefits of aspirin? To address this question, researchers in Hong Kong recruited consecutive patients who presented with overt signs of upper gastrointestinal bleeding and who were taking low-dose aspirin (≤325 mg/day) for cardiovascular or cerebrovascular indications other than primary prophylaxis. After undergoing successful endoscopic therapy and receiving high-dose intravenous proton-pump inhibitor (PPI) therapy, 156 patients (mean age, 74) were randomized to receive either placebo or 80 mg/day of aspirin for 8 weeks. Both groups received…